BCL2 and cancer: As shown in Figure 6, bax protein levels were significantly (p < 0.001) increased after treatment with azilsartan in MCF-7 and MDA-MB-231 cancer cells, compared to untreated cells; bcl2 levels were notably (p < 0.05, p < 0.01) decreased in MCF-7 and MDA-MB-231, respectively, compared to untreated cells.